Bevacizumab vs Dacarbazine in Metastatic Melanoma

Inclusion Criteria: * Previously treated or untreated, histologically confirmed, metastatic and unresectable melanoma with progressive disease * Both BRAF wild type patients as well as BRAF mutated patients are allowed. For BRAF mutated patients, BRAF targeting agents should be considered in first line if otherwise indicated and no contraindications exist. * WHO performance status 0-1 * Age \>18 years, * Known BRAF mutation * Able to undergo outpatient treatment * Patients must have clinically and/or radiographically documented measurable disease according to RECIST. * All radiology studies must be performed within 28 days prior to registration (35 days if negative). * At least 4 weeks since adjuvant interferon alpha * At least 4 weeks since 1st line treatment in case of metastasis * Major surgical procedure or significant traumatic injury \> 28 days prior to study treatment start. Biopsy or fine needle aspiration \> 2 days prior to study treatment start. Central venous line placement must be inserted at least 2 days prior to treatment start. * Only patients with irradiated and asymptomatic brain metastases and off dexamethasone are allowed. * Hematology: absolute granulocytes \> 1.0 x 109/L * Platelets \> 100 x 109/L * Bilirubin \< 1.5 x upper normal limit * Serum creatinine \< 1.5 x upper normal limits * LDH \< 1.5 x upper normal limit * INR \< 1.5 * Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the stu…